Haemopoietic stem cell transplantation in Australia, 1992-95: a report from the Australian Bone Marrow Transplant Recipient Registry

1997 ◽  
Vol 27 (4) ◽  
pp. 408-419 ◽  
Author(s):  
K. Atkinson ◽  
I. Nivison-Smith ◽  
T. Hawkins
Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1806-1806 ◽  
Author(s):  
Kavita Raj ◽  
Maadh Aldouri ◽  
Aloysius Ho ◽  
Antonio Pagliuca ◽  
Stephen Devereux ◽  
...  

Abstract Gemtuzumab Ozogamicin (GO) is an anti-CD33 antibody linked to the cytotoxic antibiotic calicheamycin. Its use in AML and acute promyelocytic leukaemia has been previously described and its hepatotoxic side effects highlighted. Haemopoietic stem cell transplantation is another modality used in the treatment of relapsed AML with graft versus leukaemic effect being implemented by T cells that are effective against the tumor specific antigens. However relapse can occur despite the presence of 100% donor derived T cells. We report prolonged disease free survival (DFS) following the use of GO/DLI. Patients with relapsed or refractory leukaemia AML (n=28) and myelodysplasia (n=6, RAEB1 n=5, RAEB2 n=1), median age 52 yrs (19–66) received treatment with gemtuzumab ozogamicin (GO) between January 2001 and February 2004 at King’s College Hospital. Six had previously untreated AML or MDS, 17 had AML/MDS in first relapse, 4 in second relapse, 6 were refractory and 1 was in second remission. Seventeen patients received GO with FLAG ± Idarubicin and 17 had GO alone. Complete remission (CR) was similar in both groups( 47% vs. 41%respectively). Twenty seven patients received single dose, 5 patients received 2 and 2 patients received 3 doses of GO. Twenty six patients received 9mg/m2, 4 received 6mg/m2, 3 at 3mg/m2 and 1 at 4.5mg/m2. Following GO 5 patients received conventional conditioning allogeneic HSCT (AlloHSCT), 8 received reduced intensity conditioning (RIC-HSCT) and 1 had autologous rescue. HSCT was done at a median time of 37 days (17–444) post-GO. Six out of 11 patients who underwent HSCT post GO with no DLI are alive in CR, median 810d (120–1080). Hepatotoxicity with bilirubin elevation grades 2–4 (NCI toxicity criteria)occurred in 14 patients associated with elevated AST grades 2–4 in 8 patients and hepatic veno-occlusive disease in 4 patients. Pulmonary haemorrhage occurred in 3 patients, contributing to death in one. Direct anti-globulin test positivity was observed in 6 patients causing significant haemolysis in 4. Eight patients who relapsed following HSCT received GO followed by donor leucocyte infusion. Blasts from these patients were mean 75.5% (85% median)CD33+. Three of the eight patients achieved complete remission, 2 are alive 240 and 810d post GO. Two other patients underwent repeat RIC-HSCT post-GO followed by DLI, both achieved CR, and 1 is alive at 990d. Chimerism data available for 8 patients showed 0–56% donor derived haemopoiesis pre treatment. Donor derived CD3+ cells were 26%and 47% in two patients and 100% in 2 patients pre GO/DLI. In the former two patients the first did not respond to this treatment, the second became 100% donor in the unfractionated bone marrow and in CD3+ fraction. In the latter two, unfractionated bone marrow was 0% donor derived and 56% donor derived pre treatment with these increasing to 77% and a 100% donor derived respectively with the CD3+ fraction remaining 100% donor. Five of these 8 patients acheived CR.Overall 13 patients (31.4%) achieved CR, 9 (25.7%) are alive 120–1080 days post-GO, median 810d. The overall median survival post-GO was 76 days (2–1080). Our results indicate that gemtuzumab ozogamicin in combination with DLI can benefit the subgroup of patients with AML /high risk MDS who have relapsed post haemopoietic stem cell transplant.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5744-5744
Author(s):  
Lakshmi Prabha ◽  
Kishore Kumar ◽  
Chezhian Subash ◽  
Siva Nambi

Abstract Introduction: Bone marrow transplantation is the main stay treatment for various disorders. Psychosocial morbidity associated with Bone Marrow Transplant are due to the diagnosis of a deadly disease, curative option with its associated risk of death. Several psychosocial factors influence the long-term outcome in patients. Objective: To identify Psychiatric illnesses in Indian patients undergoing hematopoietic stem cell transplantation. Materials and Methods: This cross-sectional study was conducted during the period of July 2015 to March 2017 at Institute of Haematology and Bone Marrow Transplantation, MIOT INTERNATIONAL, Chennai, India. All consecutive patients, aged 15 years and above, who fulfilled inclusion and exclusion criteria and underwent transplantation, were enrolled in this study. Psychiatric assessment comprised of a semi-structured interview based on Present Status Examination (PSE). Results: Out of 72 enrolled patients, twenty-six (36.1%) patients met the psychiatric diagnostic criteria. Adjustment disorder (43%) was more frequently encountered among the affected individuals followed by depressive illnesses (24%). Discussion: We had 36% of patients with symptoms of psychiatric illnesses. Interestingly higher percentage (54% and 41%) of psychiatric morbidity was observed in studies carried out by Leigh et al. and Sasaki respectively. Regarding diagnostic breakup among transplant patients, adjustment disorders (with symptoms of anxiety and depression) was the most frequent diagnosis (43%) in our study, which is similar to research of Sasaki. While on the other hand study done by Jenkin et al.observed higher prevalence (40%) of depression, which was the second highest psychiatric morbidity in our research. Majority of patients appeared to be mentally prepared and tolerant during transplantation and very few patients observed psychological problems. So, any sort of psychological issues encountered during transplantation has no relation with the diagnosis or the therapy per se but rather is more intricately related to the personality and personal history of the patients. Post-transplantation period seems to be highly stressful mainly due to the isolation, high vigilance, expectations, apprehension of the future and reverse barrier nursing. Therefore, most of psychiatric symptoms were observed within first week after transplantation procedure in 69% (n=18) of patients in our study. Other studies by Illescas - Rico et al. and Sasaki also noted that psychiatric disorders mainly developed after transplantation in majority of cases (68.75%). 76%(n=20) required psychotropic medicines in addition to counselling and psychotherapy Psychiatric symptoms settled in 62% (n=16) of cases during their stay in BMT unit. In this study, patients of the age group 24-45 years, were mostly affected comprising of 54% of all the individuals having psychological problems. Another study carried out by Prieto et al.on 220 patients who had recieved stem cell transplantation had however observed that younger age is one of the risk factor associated with psychiatric disorder in BMT. This clearly reflects the more stress observed in younger population secondary to transplantation. Regarding gender, it is believed that psychiatric disorders are significantly more common in females than males. However in this study, the number of males (58%) were more than the number females amongst the affected patients. There are few limitations of our study like the relatively small sample size, single centre study and limited time period. A multi-centric study is mandated to establish the findings more strongly to bring about a comprehensive care for the patients. Conclusion: Significant psychiatric morbidity (>1/3 - 36%) associated with bone marrow transplantation was observed. This study indicates the importance of psychiatric intervention during the transplant procedure as well as pre-transplant psychiatric assessment and counselling regarding transplant procedure. Keywords: Psychiatric disorder, Adjustment disorder, Hematopoietic stem cell transplantation. References Andrykowski MA.Psychological factors in bone marrow transplantation: a review and recommendation. Bone Marrow Transplant 1994; 13: 357-375, PrietoJM, BlanchJ, AtalaJ, CarrerasE, RoviraM, CireraE, et.al. Stem cell transplantation: risk factors for psychiatric morbidity. Eur J Cancer 2006; 42:514-20. Table. Table. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document